• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Enhanced amsacrine-induced mutagenesis in plateau-phase Chinese hamster ovary cells, with targeting of +1 frameshifts to free 3' ends of topoisomerase II cleavable complexes.

作者信息

Patteson K, Wang P, Povirk L F

机构信息

Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA.

出版信息

Cancer Res. 1999 Aug 1;59(15):3682-8.

PMID:10446982
Abstract

Previous work showed that the DNA double-strand cleaving agents bleomycin and neocarzinostatin were more mutagenic in plateau-phase than in log-phase cells. To determine whether topoisomerase II poisons that produce double-strand breaks by trapping of cleavable complexes would, likewise, induce mutations specific to plateau-phase cells, aprt mutations induced by amsacrine in both log-phase and plateau-phase CHO cells were analyzed. The maximum aprt mutant frequencies obtained were 7 x 10(-6) after treatment with 0.02 microM amsacrine in log phase and 27 x 10(-6) after treatment with 1 microM amsacrine in plateau phase, compared with a spontaneous frequency of < 1 x 10(-6). Base substitutions dominated the spectrum of mutations in log-phase cells, but were much less prevalent in plateau-phase cells. Both spectra also included small deletions, insertions and duplications, as well as few large-scale deletions or rearrangements. About 5% of the log-phase mutants and 16% of the plateau-phase mutants were +1 frameshifts, and all but one of these were targeted to potential free 3' termini of cleavable complexes, as determined by mapping of cleavage sites in DNA treated with topoisomerase II plus amsacrine in vitro. Thus, these insertions may arise from templated extension of the exposed 3' terminus by a DNA polymerase, followed by resealing of the strand, as shown previously for acridine-induced frameshifts in T4 phage.

摘要

相似文献

1
Enhanced amsacrine-induced mutagenesis in plateau-phase Chinese hamster ovary cells, with targeting of +1 frameshifts to free 3' ends of topoisomerase II cleavable complexes.
Cancer Res. 1999 Aug 1;59(15):3682-8.
2
A precise interchromosomal reciprocal exchange between hot spots for cleavable complex formation by topoisomerase II in amsacrine-treated Chinese hamster ovary cells.
Cancer Res. 1997 Nov 1;57(21):4699-702.
3
Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.对拓扑异构酶II催化抑制剂ICRF-159具有抗性的中国仓鼠卵巢细胞:Tyr49Phe突变赋予对双二氧哌嗪的高水平抗性。
Cancer Res. 1998 Apr 1;58(7):1460-8.
4
Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro.拓扑异构酶II抑制剂替尼泊苷在CHO细胞中诱导的小缺失和插入突变及其与体外药物刺激的DNA切割位点的比较。
J Mol Biol. 1993 Jan 5;229(1):52-66. doi: 10.1006/jmbi.1993.1007.
5
Deletion and duplication sequences induced in CHO cells by teniposide (VM-26), a topoisomerase II targeting drug, can be explained by the processing of DNA nicks produced by the drug-topoisomerase interaction.拓扑异构酶II靶向药物替尼泊苷(VM - 26)在CHO细胞中诱导产生的缺失和重复序列,可以通过药物与拓扑异构酶相互作用产生的DNA切口的加工过程来解释。
Mutat Res. 1994 Apr;312(2):67-78. doi: 10.1016/0165-1161(94)90011-6.
6
DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.DNA双链断裂修复途径与细胞对拓扑异构酶II抑制剂的耐受性
Cancer Res. 1990 Sep 15;50(18):5778-83.
7
Megabase pair deletions in mutant mammalian cells following exposure to amsacrine, an inhibitor of DNA topoisomerase II.
Cancer Res. 1994 Feb 15;54(4):1092-7.
8
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.拓扑异构酶II导向的双二氧哌嗪抗癌药物ICRF-187(右丙亚胺)在酵母和哺乳动物细胞中诱导的细胞毒性和DNA损伤的表征
BMC Pharmacol. 2004 Dec 2;4:31. doi: 10.1186/1471-2210-4-31.
9
Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.细胞ATP耗竭对拓扑异构酶II毒药的影响。依托泊苷可消除可裂解复合物的形成,但安吖啶不能。
Mol Pharmacol. 1999 Mar;55(3):424-31.
10
Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.增殖依赖性拓扑异构酶II含量作为人、小鼠和中国仓鼠卵巢细胞中抗肿瘤药物作用的决定因素。
Cancer Res. 1987 Aug 1;47(15):3973-9.